VKTX
NASD Viking Therapeutics, Inc.$28.54 ↑ +0.00 (+0.00%) Trading Up from the previous close of $28.54, $0.52 below the day’s high of $29.06
- YTD change
- -18.87%
- vs 20-day SMA
- -11.73%
- vs 200-day SMA
- -13.79%
Price ranges
Price & Performance
-5.32 (-15.79%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 71.3% away from all-time highs of $99.41
- VKTX is down 19% since the beginning of the year
- VKTX is down 9% over the past 12 months
- VKTX is down 15% over the past 1 month
- 18% of all VKTX investors are betting against VKTX
VKTX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -10.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -10.28%
- vs 8-day SMA
- -9.08%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.